Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Licenses GeneData Expressionist System for Microarray Data Analysis

 

Novartis Licenses GeneData’s Expressionist System for Microarray Data Analysis

 

 

NEW YORK, Feb 15 – Basel, Switzerland-based bioinformatics company GeneData said Thursday it has entered into a multi-year license agreement with Novartis Pharma AG for its Expressionist microarray data analysis system. 

 

The agreement is an extension of a previous collaboration between GeneData and Novartis Pharma’s Basel, Switzerland, research site that began three years ago.

 

Under the terms of the agreement, GeneData has installed Expressionist at all major Novartis Pharma research sites, where an estimated 2,000 researchers will be able to access it through the Novartis Intranet. GeneData said it integrated the system into Novartis Pharma's global functional genomics data management system.

 

A GeneData spokesman declined to comment on the financial terms of the agreement.

 

Expressionist analyzes gene expression data from various microarray technologies, including Affymetrix GeneChips and Incyte GEMs. The system offers technology-specific data quality control and statistical analysis capabilities, according to GeneData. 

 

Several large life science companies have licensed Expressionist, most recently Schering in October and Altana in August. 

 

“Our customers recognize that GeneData Expressionist is the most comprehensive system to analyze large amounts of gene expression data," said GeneData CEO Othmar Pfannes. 

 

GeneData estimates that it will pick up six to ten additional Expressionist licensees in pharmaceutical, agricultural, and biotech companies in the coming months.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.